A randomized controlled trial: Efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with helicobacter pylori infection

Helicobacter

Volumn 15, Issue 2, 2010, Pages 154-159

  Minakari, Mohammad ^a   Davarpanah Jazi, Amir Hosein ^b   Shavakhi, Ahmad ^a   Moghareabed, Neda ^a   Fatahi, Farinaz ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Azithromycin; Helicobacter pylori; Ofloxacin; Second line therapy

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BISMUTH CITRATE; CLARITHROMYCIN; OFLOXACIN; OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; NAUSEA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT DURATION; UREA BREATH TEST;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BREATH TESTS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; IRAN; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; UREA; YOUNG ADULT;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 77749233911     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00739.x     Document Type: Article

References (33)

1. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002 16 (Suppl. 1 3 15.
2. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol 1995 7 (5 427 433.
3. Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H. pylori eradication in Iran. World J Gastroenterol 2006 12 (28 4553 4556.
4. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 (6 772 781. (Pubitemid 46854190)
5. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 (2 167 180.
6. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994 272 (1 65 9.
7. Siavoshi F, Pourkhajeh AH, Merat S, Asl-Soleimani H, Heydarian E, Khatibian M, et al. Susceptibility of various strains of Helicobacter pylori to selected agents. Arch Iranian Med 2000 3 : 60 3.
8. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol 2005 11 (38 6009 6013.
9. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000 14 (1 91 5.
10. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 (11 1333 1343.
11. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 93 (12 2330 2338.
12. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004 10 (11 1656 1658.
13. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004 10 (5 668 671.
14. Gisbert JP, Pajares JM. Review article: Helicobacter pylori" rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 (6 1047 1057.
15. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 2001 64 (4 222 225.
16. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001 36 : 690.
17. Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Della CG, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996 91 (2 258 263. (Pubitemid 126734011)
18. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000 44 (8 2214 2216.
19. Wang WH, Wong BC, Mukhopadhyay AK, Berg DE, Cho CH, Lai KC, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000 14 (7 901 910.
20. Kitzis MD, Goldstein FW, Miegi M, Acar JF. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother 1990 25 (Suppl. A 15 8.
21. Osato MS, Reddy SG, Piergies AA, Bochenek WJ, Testa RT, Graham DY. Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment Pharmacol Ther 2001 15 (4 487 492.
22. Trautmann M, Riediger C, Moricke A, Vogt K, Bohr U, Glasbrenner B. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Helicobacter 1999 4 (2 113 120.
23. Boyanova L, Koumanova R, Gergova G, Popova M, Mitov I, Kovacheva Y, et al. Prevalence of resistant Helicobacter pylori isolates in Bulgarian children. J Med Microbiol 2002 51 (9 786 790.
24. Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 2002 40 (2 649 653.
25. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998 32 (7-8 785 793.
26. Anagnostopoulos GK, Kostopoulos P, Margantinis G, Tsiakos S, Arvanitidis D. Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection. J Clin Gastroenterol 2003 36 (4 325 328.
27. Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, Rivera M, et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005 37 (8 571 576.
28. Sullivan B, Coyle W, Nemec R, Dunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002 97 (10 2536 2539.
29. Branca G, Spanu T, Cammarota G, Schito AM, Gasbarrini A, Gasbarrini GB, et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents 2004 24 (5 433 438.
30. Watanabe Y, Aoyama N, Shirasaka D, Maekawa S, Kuroda K, Miki I, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003 35 (10 711 715.
31. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000 14 (1 45 50.
32. Candelli M, Nista EC, Carloni E, Pignataro G, Zocco MA, Cazzato A, et al. Treatment of H. pylori infection: a review. Curr Med Chem 2005 12 (4 375 384.
33. Neri M, Milano A, Laterza F, Di Bonaventura G, Piccolomini R, Caldarella MP, et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003 18 (8 821 827.